Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 20/20 | 0.83 |
| ▸ | CASP6 | P55212 | 19/20 | 0.83 |
| ▸ | CASP8 | Q14790 | 19/20 | 0.83 |
| ▸ | CASP7 | P55210 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22390638 | 0.91 | CASP3 (0.69) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL22390639 | 0.91 | CASP3 (0.69) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL18850541 | 0.91 | CASP3 (1.00) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL22390646 | 0.91 | CASP3 (0.69) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL22390658 | 0.90 | CASP3 (0.68) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL22390656 | 0.90 | CASP3 (0.68) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL17264147 | 0.90 | CASP3 (1.00) | CASP3CASP6CASP8 | |
| SCHEMBL22390770 | 0.89 | CASP3 (0.66) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL22390763 | 0.87 | CASP3 (0.64) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL22390778 | 0.85 | CASP3 (0.62) | CASP3CASP6CASP8CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022123062-A1 | BLOCKING CASPASE AND/OR FASL FOR PREVENTING FATAL OUTCOME IN COVID-19 PATIENTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-06-16 | — | — | WO | claimed |
| EP-3985126-B1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2026-03-04 | — | — | EP | disclosed |
| EP-4355915-B1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2026-02-04 | — | — | EP | disclosed |
| EP-3684954-B1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NON-ALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS | GENFIT (FR) | 2025-11-26 | — | — | EP | disclosed |
| EP-3612176-B1 | COMBINATION COMPRISING THE PPAR AGONIST ELAFIBRANOR AND AN ACETYL-COA CARBOXYLASE (ACC) INHIBITOR SELECTED FROM CP-640186, GEMCABENE, GS-0976 TO TREAT INFLAMMATORY, METABOLIC, FIBROTIC OR CHOLESTATIC DISEASES | GENFIT (FR) | 2025-09-17 | — | — | EP | disclosed |
| EP-4541422-A2 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | Gilead Sciences, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119462635-A | Quinoline derivatives as alpha 4 beta 7 integrin inhibitors | 吉利德科学公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119431230-A | Compounds for inhibiting alpha 4 beta 7 integrin | 吉利德科学公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20250032473-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3873900-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GILEAD SCIENCES INC (US) | 2025-01-08 | — | — | EP | disclosed |
| EP-3985126-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | Genfit (FR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3980070-A1 | METHOD FOR TREATMENT OF AT RISK PATIENTS | Genfit (FR) | 2022-04-13 | — | — | EP | disclosed |
| CN-114222730-A | Compounds for inhibiting alpha 4 beta 7 integrins | 吉利德科学公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3444011-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH EMRICASAN | Conatus Pharmaceuticals, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20190022043-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | CONATUS PHARMACEUTICALS INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-20170128519-A1 | CASPASE INHIBITORS FOR THE TREATMENT OF COLORECTAL CANCER | CONATUS PHARMACEUTICALS INC (US) | 2017-05-11 | — | — | US | disclosed |
| WO-2017079566-A1 | CASPASE INHIBITORS FOR USE IN THE TREATMENT OF LIVER CANCER | CONATUS PHARMACEUTICALS, INC. (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170100448-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITORS | CONATUS PHARMACEUTICALS INC (US) | 2017-04-13 | — | — | US | disclosed |
| US-20160213736-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE | CONATUS PHARMACEUTICALS, INC. | 2016-07-28 | — | — | US | disclosed |
| WO-2015175381-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITORS | CONATUS PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190022043-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | CASP1, CASP5, CASP2 | CASP3 5/4885CASP6 4/4885CASP8 11/4885 |
| US-20170100448-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITORS | CASP1, CASP2, CASP5 | CASP3 6/4885CASP6 10/4885CASP8 8/4885 |
| US-20170128519-A1 | CASPASE INHIBITORS FOR THE TREATMENT OF COLORECTAL CANCER | CASP3, CASP1, CASP7 | CASP3 1/4885CASP6 6/4885CASP8 12/4885 |
| US-20160213736-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE | CASP1, SERPINB1, CASP2 | CASP3 8/4885CASP6 12/4885CASP8 15/4885 |
| US-20250032473-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | CASP3 1116/4885CASP6 1165/4885CASP8 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.